Martinelli, G., Santoro, A., Gambacorti-Passerini, C., Polo, S. V., Solomon, S. R., Mukherjee, S., . . . Montesinos, P. (2022). P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL. Wiley.
Chicago Style (17th ed.) CitationMartinelli, G., et al. P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL. Wiley, 2022.
MLA (9th ed.) CitationMartinelli, G., et al. P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL. Wiley, 2022.
Warning: These citations may not always be 100% accurate.